Neurophth

Dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.

Launch date

Jul 2016

Employees

Market cap

Enterprise valuation

€438m (Public information from Aug 2023)

Wuhan Hubei (HQ)

Date	Investors	Amount	Round
Aug 2018*	Northern Light Venture Capital Miracle Light Fund Mint Angel Fund	CNY15.0m	Seed
Apr 2020*	Fosun Group HongShan	CNY130m	Series A
Feb 2021	Northern Light Venture Capital Oriza Holdings Harvest Capital HongShan InnoVision Capital Guofang Capital Grand Mount Capital	CNY400m	Series B
Nov 2021*	CMG-SDIC Capital	$60.0m	Series C
Aug 2023*	Zhejiang Paradise Silicon Valley Asset Management Group Guangzhou Finance Holdings SDIC China Merchants Yangtze River Fund CMB International Capital Corporation Hubei Science and Technology Investment Wuhan Hi-Tech State-owned Holding	CNY700m Valuation: CNY3.5b	Series C
Total Funding		€210m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Neurophth